Results | Infant fulminant hepatitis mortality rates and sexadjusted rate ratios declined significantly for infants born from 1977 -1980 to 2009 -2011 . The decline was greatest from 1981-1984 to 1985-1988 and from 1989-1992 to 1993-1996, coincident with the launch of the national immunization program in 1984 and the change to recombinant vaccines in 1992. Compared with 1977 Compared with -1980 , the sexadjusted rate ratio declined to 0.88 (95% CI, 0.65-1.21) in There was a continuous decline in age-and sex-adjusted rate ratios of CLD and HCC mortality and HCC incidence for birth cohorts born after implementation of the program. The birth cohort born in 1981-1984, which received HBV vaccines at preschool ages instead of early infancy, had significantly lower CLD and HCC mortality and HCC incidence than those born in 1977-1980. The age-and sex-adjusted rate ratio in 2001-2004 was 0.11 (95% CI, 0.02-0.80) for CLD mortality, 0.08 (95% CI, 0.02-0.34) for HCC mortality, and 0.20 (95% CI, 0.06-0.65) for HCC incidence.
Males had significantly higher CLD and HCC mortality and HCC incidence than females in most age groups (Figure) . The 1985-2006 birth cohorts had significantly lower CLD and HCC mortality and HCC incidence rates than those born in 1977-1984 for both sexes.
Discussion | The mortality of IFH in vaccinated birth cohorts decreased by more than 90% from 1977-1980 to 2009-2011, which was greater than the previously reported reduction (approximately 70%) from 1975-1984 to 1985-1998. 4 This long-term, high-coverage immunization program was associated with lower IFH mortality through increasing individual and herd immunity of vaccinated cohorts. From 1977 From -1980 From to 2001 From -2004 , the age-and sex-adjusted rate ratios for individuals aged 5 to 29 years decreased by more than 90% for CLD and HCC mortality and by more than 80% for HCC incidence, which were higher than the previously reported reduction (70%) in HCC incidence for youth aged 6 to 19 years. 3 The national HBV therapy program launched in November 2003 may also be contributing to the reduction in risk of IFH, CLD, and HCC; however, this contribution is likely minimal because few members of the study cohorts were eligible for therapy. Hepatitis B virus immunization in infancy has been associated with a reduction in the risk of IFH, CLD, and HCC in Taiwan. 
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COMMENT & RESPONSE
Genetic Variants Associated With Susceptibility to Helicobacter pylori
To the Editor The study by Dr Mayerle and collegues 1 found a strong association between variants at the toll-like receptor 10, 1, and 6 (TLR10/1/6) locus on chromosome 4 and Helicobacter pylori serologic status, which contributes to the understanding of host susceptibility to a common infectious disease. During the process of evaluating the functional significance of their finding, the authors presented results that indicate that a singlenucleotide polymorphism within this locus (rs10004195), which was identified as having the strongest association with H pylori seroprevalence, may be an expression quantitative trait locus causing reduced expression of TLR1. They suggested that decreased TLR1 messenger RNA expression or defective protein function, or both, might be responsible for the observed association with protection from the acquisition of H pylori seropositivity.
We would like to provide a modified interpretation of these findings given that prior studies have demonstrated that coding polymorphisms in the TLR1 locus linked to rs10004195 are actually associated with increased leukocyte responses to TLR1/TLR2 agonists. As the authors stated, there are 2 nonsynonymous variants within TLR1 that are in almost perfect linkage disequilibrium with rs10004195, rs4833095 (Asn248Ser), and rs5743518 (Ser602Ile). These nonsynonymous polymorphisms are associated with changes in surface expression of the TLR1 protein, but not with changes in messenger RNA or total cell protein levels. 2, 3 In whites, the minor alleles of these coding variants (Ser and Ile) have been shown to be associated with surface expression of TLR1 on monocytes, whereas cells from homozygotes for the common allele have no TLR1 on their surface. 2,3 Candidate gene and genome-wide association studies have shown that leukocytes carrying the minor alleles at rs4833095 and rs5743618 demonstrate increased responses to agonists for TLR1/TLR2, 2-4 and patients carrying these alleles are at increased risk for several clinical phenotypes, including sepsisrelated death 3 and altered immune responses to the BCG vaccine. 5 These functional effects do not correlate with TLR1 messenger RNA expression and would not be detected with the cis-expression quantitative trait locus method used by Mayerle et al. 1 Thus, we believe the literature supports that increased (not decreased) TLR1/TLR2-mediated responses could be the protective factor responsible for the decreased prevalence of H pylori serologic status in the study populations. This is a potentially important distinction as the implications for H pylori-related disease and other microbial infections are determined.
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